top
Search terms
Results 1 - 10 of 18 - ordered by :
Pages: 1 2
Ehjcvp

Proton pump inhibitor use by aspirin-treated coronary artery disease patients is not associated with increased risk of cardiovascular events Introduction Cardiovascular disease (CVD) is widespread, ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLES, Laura A. Fortuna, Pamala A. Pawloski, Emily D. Parker, Nicole K. Trower, Thomas E. Kottke

Date : 01/01/2016 Item size : 263457 bytes
Ehjcvp

Vice versa, patients presenting with acute coronary syndromes (ACS) develop AF in 621% of cases, hence, through the presence of vascular disease, these patients automatically require anticoagulation ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Miklos Rohla, Thomas W. Weiss, Johann Wojta, Alexander Niessner, Kurt Huber

Date : 01/07/2015 Item size : 293945 bytes
Ehjcvp

Abstract Aims We compared clinical outcomes in patients with AF with and without diabetes in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLE, Justin A. Ezekowitz, Basil S. Lewis, Renato D. Lopes, Daniel M. Wojdyla, John J.V. McMurray, Michael Hanna, Dan Atar, M. ...

Date : 01/04/2015 Item size : 304584 bytes
Ehjcvp

Effect of rapid desensitization on platelet inhibition and basophil activation in patients with aspirin hypersensitivity and coronary disease Cases were patients with coronary artery disease (CAD) ...

European Heart Journal - Cardiovascular Pharmacotherapy, Original Article, Stéphane Manzo-Silberman, Pascale Nicaise-Roland, Catherine Neukirch, Florence Tubach, Marie-Geneviève Huisse, Sylvie ...

Date : 05/08/2016 Item size : 209243 bytes
Ehjcvp

Introduction Dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a P2Y12 inhibitor, is recommended by guidelines for up to 12 months in patients with acute coronary ...

European Heart Journal - Cardiovascular Pharmacotherapy, Original Articles, Gianluigi Savarese, Stefano Savonitto, Lars H. Lund, Stefania Paolillo, Caterina Marciano, Santo Dellegrottaglie, Antonio ...

Date : 01/10/2016 Item size : 333679 bytes
Ehjcvp

[...]SGLT2 inhibition represents a novel treatment, which might be a promising target not only to (further) reduce blood glucose but also to target other cardiovascular risk factors. SGLT2 ...

European Heart Journal - Cardiovascular Pharmacotherapy, Review, Anne E. de Leeuw, Rudolf A. de Boer

Date : 01/10/2016 Item size : 586778 bytes
Ehjcvp

The EMPA-REG outcome trial showed improved survival and less hospitalization for HF: it is changing concepts and practice.1 The new era of outcome trials follows the acute awareness of the need to ...

European Heart Journal - Cardiovascular Pharmacotherapy, Editorials, Basil S. Lewis

Date : 01/10/2016 Item size : 203582 bytes
Ehjcvp

[...]SGLT2 inhibition represents a novel treatment, which might be a promising target not only to (further) reduce blood glucose but also to target other cardiovascular risk factors. SGLT2 ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEW, Anne E. de Leeuw, Rudolf A. de Boer

Date : 18/04/2016 Item size : 590679 bytes
Ehjcvp

In this issue of European Heart Journal Cardiovascular Pharmacology a substudy of the Italian EYESHOT Registry focused on medically managed patients is published.1 In it, the authors describe the ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIAL, Héctor Bueno

Date : 01/07/2015 Item size : 219771 bytes
Ehjcvp

Abstract Aims Therapeutic windows for residual platelet reactivity in patients with coronary artery disease on P2Y12 inhibitors were proposed in a consensus document. Conclusions Our results suggest ...

European Heart Journal - Cardiovascular Pharmacotherapy, Original Article, Minka J.A. Vries, Heleen J. Bouman, Renske H. Olie, Leo F. Veenstra, Suzanne Zwaveling, Paul W.M. Verhezen, Arina J. ten ...

Date : 01/01/2017 Item size : 286116 bytes